Estrogen treatment and the risk of endometrial cancer
Persson, I.
Lakartidningen 81(20): 2068-2071
1984
ISSN/ISBN: 0023-7205 PMID: 6727480 Document Number: 227984
Document emailed within 1 workday
Related Documents
Magnusson, C.; Weiderpass, E. 2001: Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer Lakartidningen 98(5): 418-421Vishnevskiĭ, A.S.; Bokhman, I.V. 1980: Estrogen treatment and endometrial cancer Akusherstvo i Ginekologiia 6: 11-16
Hausknecht, R.U.; Gusberg, S.B. 1969: Estrogen metabolism in patients at high risk for endometrial carcinoma. I. Urinary metabolites of H3-estradiol in normal postmenopausal women and those with endometrial carcinoma American Journal of Obstetrics and Gynecology 105(8): 1161-1167
Thurzó, L. 1990: Response of estrogen and progesterone receptors to treatment with large doses of progestogen (depo-provera) in endometrial cancer Zentralblatt für Gynakologie 112(17): 1111-1115
Felix, A.S.; Gaudet, M.M.; La Vecchia, C.; Nagle, C.M.; Shu, X.O.; Weiderpass, E.; Adami, H.O.; Beresford, S.; Bernstein, L.; Chen, C.; Cook, L.S.; De Vivo, I.; Doherty, J.A.; Friedenreich, C.M.; Gapstur, S.M.; Hill, D.; Horn-Ross, P.L.; Lacey, J.V.; Levi, F.; Liang, X.; Lu, L.; Magliocco, A.; McCann, S.E.; Negri, E.; Olson, S.H.; Palmer, J.R.; Patel, A.V.; Petruzella, S.; Prescott, J.; Risch, H.A.; Rosenberg, L.; Sherman, M.E.; Spurdle, A.B.; Webb, P.M.; Wise, L.A.; Xiang, Y.-B.; Xu, W.; Yang, H.P.; Yu, H.; Zeleniuch-Jacquotte, A.; Brinton, L.A. 2015: Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium International Journal of Cancer 136(5): E410-E422
Mangili, G.; De Marzi, P.; Viganò, R.; Rabaiotti, E.; Sassi, I.; Taccagni, G.L.; Garancini, P.; Frigerio, L. 2002: Identification of high risk patients with endometrial carcinoma. Prognostic assessment of endometrial cancer European Journal of Gynaecological Oncology 23(3): 216-220
Bertelsen, C.A.; Andreasson, B. 1998: Estrogen replacement to women treated for endometrial cancer Ugeskrift for Laeger 160(12): 1777-1780
Sledge, G.W.; Ramzy, I.; Dressler, L.G.; Dorr, F.A.; Adams, D.J.; McGuire, W.L. 1985: Presence of an estrogen-regulated protein in endometrial cancer Obstetrics and Gynecology 66(3): 423-427
Caringella, A.M.; Di Naro, E.; Loverro, G. 2011: Clinical function of estrogen receptors in endometrial cancer Minerva Ginecologica 63(6): 495-504
Neri, F.; Maggino, T. 2009: Surveillance of endometrial pathologies, especially for endometrial cancer, of breast cancer patients under tamoxifen treatment European Journal of Gynaecological Oncology 30(4): 357-360
Horwitz, R.I.; Feinstein, A.R. 1979: Intravaginal estrogen creams and endometrial cancer: no causal association found JAMA 241(12): 1266-1267
Audet-Lapointe, P.; Ayoub, J.; Methot, Y. 1988: An innovative protocol, cyclic hormone-chemotherapy in the treatment of high-risk localized endometrial cancer Journal de Gynecologie Obstetrique et Biologie de la Reproduction 17(6): 751-755
Tomica, D.; Ramić, S.; Danolić, D.; Knezević, F.; Kolak, T.; Balja, M.P.ć; Alvir, I.; Mamić, I.; Puljiz, M. 2014: A correlation between the expression of estrogen receptors and progesterone receptors in cancer cells and in the myometrium and prognostic factors in endometrial cancer Collegium Antropologicum 38(1): 129-134
Meissner, W.A.; Sommers, S.C.; Sherman, G. 1957: Endometrial hyperplasia, endometrial carcinoma, and endometriosis produced experimentally by estrogen Cancer 10(3): 500-509
Dargent, D. 2000: Estrogen replacement therapy in patients in remission after treatment for estrogen dependent cancer. Certainties are still lacking Gynecologie Obstetrique and Fertilite 28(6): 427-428
Fujimoto, J.; Hori, M.; Ichigo, S.; Tamaya, T. 1997: Antiestrogenic compounds inhibit estrogen-induced expression of fibroblast growth factor family (FGF-1, 2, and 4) mRNA in well-differentiated endometrial cancer cells European Journal of Gynaecological Oncology 18(6): 497-501
Fedele, L.; Marchini, M.; Cavalli, G.; Baglioni, A.; Taccagni, G.L. 1987: Marked deciliation and insufficient secretory modification of endometrial surface during treatment with a new progestogen-estrogen combination Contraception 35(5): 497-505
Segreti, E.M.; Novotny, D.B.; Soper, J.T.; Mutch, D.G.; Creasman, W.T.; McCarty, K.S. 1989: Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor Obstetrics and Gynecology 73(5 Pt 1): 780-785
Echeverría, O.M.; Thampan, R.V.; Juárez-Chavero, S.; Hernández-Pérez, A.D.; Ortiz, R.; Vázquez-Nin, G.H. 2005: Immunocytochemical study of estrogen receptor activation factor (E-RAF) and the proteins that interact with nuclear estrogen receptor II (nER II) in epithelial endometrial cells, in the presence and in the absence of estradiol European Journal of Histochemistry: Ejh 49(1): 67-74
Benshushan, A.; Paltiel, O.; Rojansky, N.; Brzezinski, A.; Laufer, N. 2002: IUD use and the risk of endometrial cancer European Journal of Obstetrics Gynecology and Reproductive Biology 105(2): 166-169